N Engl J Med 2014 Oct;371(17):1599-608
From St. George's, University of London (A.J., D.A.M., T.S.H., D.C., P.D.B.), Medical Research Council Clinical Trials Unit at University College London (A.J.N., P.P.J.P., H.E.C.), and University College London Centre for Clinical Biology, University College London (A.L.E.B., T.D.M.), London; Aurum Institute (G.J.C., S.C.) and School of Public Health, University of the Witwatersrand (G.J.C.), Johannesburg, and South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health (M.H., H.G.) and Division of Clinical Pharmacology, Department of Medicine (H.M.M., S.P.Z.), University of Cape Town, Cape Town - all in South Africa; Harare City Health Department, Harare (S.M., N.A.S.S.), and Medical Directorate of Mashonaland East, Marondera (S.Z., L.M.) - both in Zimbabwe; CDC, Gaborone, Botswana (J.S., S.N.); and Macha Research Trust, Macha, Zambia (J.H.D.).